CLTC and neoplasm: Therapeutic vaccination with the mutated CLTC peptide, polyI:C, and α-PD-1 significantly reduces both the frequency and total number of NeoAg-specific Tregs in both the tdLN and TME 18 days after tumor inoculation (Figure 2c and 3d).